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ABSTRACT 
Purpose of review: HIV-associated cryptococcal meningitis (CM) remains a significant 
contributor to AIDS-related mortality despite widened access to antiretroviral therapy. Even 
in clinical trial settings 10-week mortality is roughly 40%. A number of important clinical 
trials have either recently concluded or are actively recruiting. 
 
Recent findings: Global burden of disease etimates suggest CM causes 181,100 deaths 
annualy. Screening blood for cryptococcal antigen (CrAg) in HIV-infected individuals with 
CD4 cell counts <100 cells/µL and pre-emptive antifungal treatment for those with 
detectable CrAg reduces the incidence of CM and is likely to reduce mortality. CM treatment 
with conventional 14-day courses of amphotericin are associated with high toxicity and 
mortality and can be reduced to seven days if given alongside flucytosine. Flucytosine is a 
significantly superior adjunct to amphotericin treatment compared to fluconazole. In 
settings without amphotericin B dual oral antifungal combinations of flucytosine and 
fluconazole offer an effective alternative treatment. A single, high-dose of liposomal 
amphotericin is effective at reducing fungal burden and is being tested in a phase III trial. 
 
Summary: Recently completed and ongoing clinical trials are increasing our understanding 
of how to optimise induction therapy for CM. Advocacy efforts are needed to broaden 
access to amphotericin formulations and flucytosine. 
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 INTRODUCTION 
HIV-associated cryptococcal meningitis (CM) remains a significant contributor to AIDS-
related mortality globally, despite roll-out of antiretroviral therapy (ART) (1). Treatment in 
low and middle income countries (LMICs) is often based on 14-day courses of amphotericin 
B and fluconazole which is associated with a ten-week mortality of roughly 40%(2, 3). A 
number of important clinical trials have either recently completed or are currently recruiting 
participants to help reduce these high mortality rates(2-4). In this paper, we discuss recent 
trends in the epidemiology of CM, innovation in diagnosis and screening, and discuss the 
findings of recently completed randomised controlled trials. 
 
EPIDEMIOLOGY 
A recent systematic review examining the global prevalence of cryptococcal antigenaemia 
(CrAg) in HIV-infected individuals with low CD4 cell counts found a pooled global CrAg 
prevalence of 6.5% in individuals with CD4<100 cells/µl, and 2% among those with CD4 
counts 101-200 cells/µl(5). Updated global burden of disease estimates suggest there were 
approximately 278,000 HIV-infected people positive for CrAg, and an estimated 223,100 
incident cases of CM globally in 2014, with 73% of these occurring in sub-Saharan Africa. 
Annual global deaths from CM were estimated at 181,100 (Figure 1)(1). Globally, CM is 
responsible for roughly 15% of AIDS-related deaths and is associated with significant long-
term disability(6, 7). 
 
In Botswana, one of the first countries in sub-Saharan Africa to implement a country-wide 
ART programme, despite excellent ART coverage there is still a substantial burden of 
advanced HIV, with the 2013-2014 incidence of CM comparable to pre-ART era rates seen in 
South Africa(8). Data from South Africa also show minimal or no recent decline in the 
number of CM cases  with widespread ART roll out(9). This is likely to result from increasing 
numbers of patients on long-term ART interrupting, stopping, or failing therapy, offsetting 
any decline in the numbers of patients presenting for the first time with advanced HIV-
disease. The number of patients in South Africa with a CD4 <100 cells/uL and the proportion 
of those who are CrAg positive does not appear to have changed in recent years, however 
51% of patients with a CD4 <50cells/uL are now ART experienced(9, 10). Similarly, in 
Kampala, Uganda, 59% of patients presenting with CM are now ART experienced (11). These 
studies highlight the growing complexity of CM patients who often have ART resistance and 
difficulty with adherence.  
 
DIAGNOSTICS  
Although the gold standard for CM diagnosis remains a positive cryptococcus CSF culture, 
the current mainstay of cryptococcal diagnosis is the detection of CrAg, a polysaccharide of 
the cryptococcal capsule which is shed in CSF and blood (Figure 2). CM diagnosis has been 
revolutionised by the widespread availability of reliable point-of-care Lateral Flow Assays 
(LFAs) which detect CrAg. The IMMY LFA remains the most sensitive and specific rapid 
diagnostic test (RDT) available(12). A potential substitute to the IMMY LFA, the StrongStep, 
was found to have low sensitivity when used on plasma(12). A recently developed RDT, the 
semi-quantitative Biosynex/BioRad Crypto PS test, incorporates an additional positive line 
aimed to detect high titers of CrAg in both blood and CSF. Preliminary results from 
Cameroon found this test to have comparable performance to the IMMY LFA for antigen 
screening(13), however further validation in larger studies is needed. 
 In areas where CrAg tests are not available the alternative rapid test is India Ink staining of 
CSF, but sensitivity is around 70%(14). A study in Uganda has shown that acridine orange, 
which stains fungal nucleic acids rather than the capsule, was more sensitive than India ink 
(96% vs 69%) with reference to CrAg (14). 
 
Cryptococcal colony forming units (CFUs) can be counted on serially diluted samples of CSF 
to enable the quantification of fungal burden, and have been shown to be a strong 
prognostic indicator(15). However, such quantitative cultures are time consuming and 
difficult to perform, hence alternatives methods to rapidly assess fungal burden are needed. 
Trypan blue staining and automated cell counting using the TC20 automated cell counter 
has been evaluated in Uganda, but found to be poorly predictive of quantitative CFU counts 
(16). Flow cytometry using a BD LSRFortessa flow cytometer did provide a rapid and 
accurate measurement of fungal burden in patients with CM in a small pilot study in South 
Africa(17), providing proof or principle for the technique, and if combined with a 
cryptococcal viability stain(18), could potentially be used to assess the response to 
treatment. Another alternative to quantitative culture is a quantitative polymerase chain 
reaction (PCR) test for cryptococcus in both blood and CSF being developed by researchers 
at the Institut Pasteur. 
 
PREVENTION 
CrAg can be detected in the blood many weeks before the onset of CM symptoms(19). WHO 
guidelines recommended CrAg screening as the preferred CM prevention strategy in all 
patients with a CD4 <100 cells/μL(20). Patients who test positive for serum CrAg should be 
screened for symptoms of CM, and ideally offered a lumbar puncture even in the absence of 
meningitis symptoms. In cases where patients decline a lumbar puncture, and for all 
patients without evidence of meningitis, high-dose pre-emptive fluconazole (800-
1200mg/day) is recommended for two weeks followed by standard fluconazole 
consolidation and maintenance treatment(20). The importance of performing CSF analysis 
to identify patients in need of more intensive treatment was highlighted in a recent South 
frican study showing that 34% of asymptomatic CrAg positive patients had CM(21).  A 
systematic review and meta-analysis of CrAg screening studies assessing the prevalence of 
asymptomatic CM in CrAg positive patients, the incidence of CM, and all-cause mortality 
rates, reported a pooled prevalence of asymptomatic CM in CrAg positive participants of 
33% (95% CI, 21-45%). The incidence of CM in CrAg positive individuals was 21.4% (95% CI, 
11.6-34.4%) without preemptive fluconazole and 5.7% (95% CI, 3.0-9.7%) with preemptive 
fluconazole therapy initiated at 800mg/day(22).  
 
National CrAg screening programmes have now been implemented in several African 
countries, with economic analyses suggesting the intervention should be cost-effective in 
African settings(23, 24). However, early implementation has been challenging, with low 
rates of uptake when testing is left to the discretion of individual clinicians(25), suggesting 
automatic, or “reflex” screening of CD4 samples with low CD4 counts is preferable. Even 
with reflex screening strategies, losses to follow-up or delays in receiving and acting on CrAg 
results can adversely impact the effectiveness of the intervention(26). Point of care CrAg 
testing may avoid these losses and delays(27), and the IMMY CrAg assay can be performed 
effectively on finger prick blood samples(28). In settings where CrAg screening is not 
possible, primary fluconazole prophylaxis remains an option for CM prevention in 
individuals with advanced HIV-disease(20), with recent data confirming its effectiveness in 
reducing the incidence of cryptococcal disease(29).  
TREATMENT 
The treatment of HIV-associated CM is formed of three phases. An initial two-week 
induction phase, an eight-week consolidation phase of fluconazole 800mg/day and 
maintenance with fluconazole 200mg/day until the CD4 count reaches >200 cells/μL. Until 
recently the WHO recommended 14-days of daily intravenous amphotericin B given with 
oral flucytosine or fluconazole for induction therapy in low and middle income countries 
(LMICs). The recent Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) trial 
aimed to determine whether amphotericin can be given for seven rather than 14 days; 
determine the efficacy of flucytosine compared to fluconazole as the oral partner drug to 
amphotericin B; and test a dual oral antifungal combination(2). A total of 721 patients were 
randomised to one of five arms: (i) 14-days of amphotericin B with flucytosine; (ii) 14-days 
of amphotericin B with fluconazole; (iii) Seven-days of amphotericin B with flucytosine, (iv) 
Seven-days of amphotericin B with fluconazole; (v) 14-days of flucytosine and fluconazole. 
Pooled analysis of patients receiving amphotericin B demonstrated that seven days was 
non-inferior to 14 days in terms of all-cause mortality (Figure 3). Among those taking 
flucytosine as the partner drug, 7 days of amphotericin B had lower ten-week mortality 
(24%, 95% CI: 16-32%) compared to 14-days of amphotericin B plus flucytosine(38%, 95% CI: 
29-32%, hazard ratio 0.56, 95% CI: 0.35-0.91). Notably, the poorest performing arm of the 
ACTA trial was seven-days amphotericin B plus fluconazole, so a reduction from 14 to seven-
days of amphotericin B is only possible in contexts where flucytosine is available. One week 
of amphotericin B was associated with less drug-induced toxicity, a reduced need for 
laboratory monitoring, shorter hospital admissions and fewer adverse effects such as 
anaemia requiring blood transfusions. ACTA also confirmed that flucytosine is a significantly 
superior partner drug for amphotericin B based treatments, leading to a substantial 
mortality reduction of 38%(95% CI: 16-55%, p=0.002) compared to fluconazole. The oral 
combination arm (fluconazole and flucytosine) was the second best performing arm with a 
10-week mortality of 35%(95% CI 29-41%). In light of these trial data, and a subsequent 
Cochrane review(30), updated WHO guidelines recommended first-line induction treatment 
of seven-days of amphotericin B and flucytosine 100mg/kg/day, followed by seven-days of 
fluconazole 1200mg/day (Table 1)(20).  
 
In high-income settings, an alternative induction regimen is 14-days of liposomal 
amphotericin and flucytosine(31). Liposomal amphotericin (L-AmB) is associated with fewer 
drug induced toxicities than the standard deoxycholate formulation, and well suited for use 
in short-course induction treatment due to the potential for high dosing made possible by 
the lower rates of toxicity, the long tissue half-life and its effective penetration into brain 
tissue(32). The recently completed AMBITION phase II trial was performed with the primary 
objective of determining the rate of clearance of cryptococcus from the cerebrospinal fluid, 
the Early Fungicidal Activity (EFA), of three alternative schedules of intermittent high dose L-
AmB in comparison with standard daily L-AmB(4). Eighty participants were recruited at sites 
in Botswana and Tanzania and randomised to one of four treatment arms: (i) L-AmB 10 
mg/kg day one (single dose); (ii) L-AmB 10 mg/kg day one, L-AmB 5 mg/kg day three (two 
doses); (iii) L-AmB 10 mg/kg day one, L-AmB 5 mg/kg days three and seven (three doses). 
The control arm (iv) was standard 14-day L-AmB (3mg/kg/day). All were given with high 
dose fluconazole (1200mg/day). The primary analysis showed that the EFA in all three short-
course high-dose arms was non-inferior to the control arm. There was no evidence for any 
dose response effect with additional L-AmB doses, suggesting maximal fungicidal activity 
was achieved with a single 10mg/kg dose(33).  The AMBITION phase III trial is currently 
comparing a single, high-dose of L-AmB given with 14-days of flucytosine and fluconazole 
against the current WHO recommended first-line regimen (ISRCTN: 72509687).  
 
Alternative antifungal agents 
The recently completed adjunctive sertraline for the treatment of HIV-associated 
cryptococcal meningitis (ASTRO) phase III trial explored the addition of sertraline to 
standard induction with amphotericin and fluconazole, which had shown some promise in a 
phase II trial(34). Unfortunately, this trial was stopped after recruiting 460 of a planned 550 
patients as there was found to be no impact on mortality(35). In an ongoing search for other 
drugs that could be repurposed, one research team in Vietnam are currently recruiting 
patients to a phase II trial adding tamoxifen to the standard induction regimen with results 
expected in 2019. Researchers in the USA have developed a new investigational fungal 
Cyp51 inhibitor called VT-1129 which has demonstrated potent in vitro activity against 
cryptococcus(36). Finally, the antihelmith drug flubendazole has shown potential 
promise(37), along with multiple calcium channel blockers demonstrating action against 
cryptococcus(38). To date, no clinical trial has been conducted using these agents. 
 
Steroids 
The CRYPTODEX placebo-controlled trial investigated the role of adjunctive dexamethasone 
during the first six weeks of CM treatment and was conducted in six counties across Africa 
and Asia(3). The trial was stopped after the recruitment of 451 patients at the planned mid-
point interim analysis which found that steroids did not reduce mortality, significantly 
increased adverse events and disability, and led to slower rates of decline in EFA. 
Dexamethasone increased the rate of decline in CSF TNF-α, which could be an explanation 
for the slower fungal clearance and poor outcomes(39). Steroids are therefore not a suitable 
adjunctive treatment during the induction phase, but continue to play a role in the 
treatment of CM immune reconstitution inflammatory syndrome (IRIS)(20).  
 
Neurapheresis 
A research group in the USA have recently published a proof of concept using an animal 
model wherein they filtered cryptococcus out of the CSF of rabbits using a process called 
neurapheresis(40). This approach is in its infancy but warrants further exploration. 
 
Therapeutic Lumbar Punctures 
Lumbar punctures are also essential for the recognition and effective management of raised 
intracranial pressure (ICP) which is associated with improved outcomes(41). In many high-
burden settings manometers are not reliably available. As an alternative in such settings, 
one study in South Africa found the optimal cut-off value for defining high pressure using a 
standard 22-G spinal needle is ≥40 drops/min(42). In additional to a shortage of equipment, 
clinicians must often navigate complex cultural barriers to obtaining CSF samples in 
circumstances whereby patients refuse LP, either for fear of pain – compounded by limited 
used of local anaesthetic – or concerns that LPs cause death(43).  
 
ANTIRETROVIRAL THERAPY AND IRIS 
IRIS remains a significant complication of CM. Individuals presenting with a first episode of 
CM manifesting as an unmasking IRIS may suffer worse outcomes than those who have 
been ART exposed (44). A recent Cochrane review has appraised four trials comparing the 
impact of early ART (within the first four weeks of antifungal initiation) compared with 
delayed ART (after four weeks) and has concluded that ART should be delayed until at least 
four weeks due to a potential higher risk of mortality among early initiators(45). 
 
The specific host and pathogen attributes that lead to the development of CM-IRIS are still 
not fully understood. Development of CM-IRIS has been strongly associated with high 
central nervous system (CNS) expression of the chemokines MCP-1(CCL2) and MIP-1α(CCL3) 
at initial CM presentation. It is hypothesised that when immune restoration occurs this 
leads to an influx of inflammatory cells into the CNS, excessive dysregulated local 
inflammation, and IRIS(46, 47). A recent study has shown lower levels of plasma IgM 
antibodies to some of the cryptococcal polysaccharide antigens and total plasma IgM  in 
cases of CM-IRIS(48), although the role of antibody-mediated protection in CM remains 
uncertain. This observation may indicate an important role for antibody-mediated 
protection during CM, and fit with the overarching hypothesis that a poor initial immune 
response and subsequent failure of effective immune clearance of cryptococcal antigens are 
key predisposing factors for IRIS (49).  
 
ADVOCACY 
Increasing access to L-AmB in LMICs will help reduce the drug induced toxicities 
encountered with conventional amphotericin B. Gilead have recently announced an 
expansion of their preferential pricing programme for visceral leishmaniasis to include CM 
which could have a dramatic impact on mortality(50). In addition the FDA have recently 
included treatments for CM in their priorty review voucher scheme which could spur further 
drug development in this field(51). Furthermore, despite the strong evidence supporting the 
use of flucytosine for the treatment of CM, flucytosine remains unregistered and 
unavailable in African and Asian LMICs with very few companies manufacturing the drug. It 
is hoped that with an increasing acknowledgement of the role of flucytosine its production, 
registration and distribution will broaden(52).  
 
CONCLUSION 
Cryptococcal meningitis continues to pose a major clinical challenge in resource limited 
settings. Screening and diagnosis have been revolutionised by the highly sensitive lateral 
flow assay, and seminal clinical trials have improved our understanding of how to optimise 
induction therapy, with shorter-courses of amphotericin given with flucytosine to reduce 
mortality rates, and the avoidance of harmful adjunctive steroids. However, advocacy 
efforts are urgently needed to ensure that patients with CM have access to these novel 
diagnostics and treatments so that recent advances in evidence can be translated into 
clinical practice. 
 
KEY POINTS 
 Cryptococcal meningitis remains a significant cause of AIDS-associated mortality 
 Treatment with conventional 14-day courses of amphotericin are associated with 
high toxicity and mortality and can be reduced to seven days if given alongside 
flucytosine.  
 Flucytosine is a significantly superior adjunct to amphotericin treatment compared 
to fluconazole.  
 A single, high-dose of liposomal amphotericin is effective at reducing fungal burden 
and is being tested in a phase III trial. 
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Figure 1 (previously published): Estimated annual incidence of cryptococcal infection by 
country in 2014(1) 
 
Figure 2 (original): Negative and positive cryptococcal antigen lateral flow assay (left), 
cryptococcal culture on Sabouraud agar medium (top right) and India ink staining showing 
cryptococcus in CSF (lower right). 
 
Figure 3 (previously published): Cumulative all cause mortality from the ACTA trial(2).  
A: Cumulative all-cause mortality by week 10 according to treatment arm. 
B: Comparison of cumulative all-cause mortality by week 10 between flucytosine and 
fluconazole as amphotericin B partner treatment 
C: Cumulative all-cause mortality by week 10 according to the treatment strategy 
 
Table 1 (original): WHO 2018 guidelines for management of cryptococcal disease in HIV-
infected adults (20). 
